Anuh Pharma has signed an Asset Transfer Agreement to acquire a manufacturing facility from Vanquest Pharma for ₹72.90 crore. The deal is expected to increase the company's production capacity by 525 MTPA.

Acquisition details

The transaction involves Anuh Pharma acquiring land, buildings, and plant and machinery from Vanquest Pharma Private Limited. The facility is located at F-10, M.I.D.C., Tarapur, Boisar, District Palghar, Maharashtra. The acquisition is aimed at strengthening the company's production capacity and market presence in manufacturing quality APIs and intermediates.

Strategic impact

The purchase of assets relates specifically to the manufacturing of APIs and intermediates. The agreed value of ₹72.90 crore excludes applicable taxes and fees. The transaction is a cash consideration deal and does not involve the issuance of any shares by Anuh Pharma. Vanquest Pharma is not related to the company's promoter group, and the transaction is not classified as a related party transaction.

What the Numbers Show

The addition of 525 MTPA in capacity represents a significant scale-up for Anuh Pharma's API segment. By acquiring an existing operational facility in the established pharmaceutical hub of Tarapur rather than greenfield construction, the company likely accelerates its time-to-market for increased volume. The deal value of ₹72.90 crore against a 525 MTPA capacity addition provides a clear metric for capital efficiency in this expansion phase.

Anuh Pharma has received board approval for a ₹75 crore loan aimed at expanding its manufacturing assets and increasing production capacity. The decision was taken during the Board of Directors meeting held on October 13, 2026.

Board approval and loan details

The board approved two related items: investment in manufacturing assets for expansion and the proposal to avail a loan of up to ₹75 crore specifically for the purchase of these assets. The loan is intended to fund the expansion of the company's production capacity. This action is subject to the finalisation of terms and conditions and the receipt of applicable approvals, wherever required.

Regulatory disclosure

Anuh Pharma stated that requisite details and annexures, to the extent applicable under the SEBI (LODR) Regulations, 2015, shall be disclosed based on the actual details of the transaction. No further specifics regarding the timeline, facility location, or product scope were disclosed at this stage. The meeting commenced at 3:30 pm and concluded at 4:35 pm.